Quatrx Pharmaceuticals Announces New Management Appointments

QUATRx Pharmaceuticals Company
777 East Eisenhower Parkway, Suite 100
Ann Arbor, MI 48108
(734) 913-9900 • fax (734) 913-0743
www.quatrx.com
Company Contact: Julia Owens
(734) 913-9900 x121
QUATRX PHARMACEUTICALS ANNOUNCES NEW MANAGEMENT
APPOINTMENTS
Rochelle Hanley, M.D., joins QuatRx as chief medical officer
ANN ARBOR, MI (September 19, 2006) -- QuatRx Pharmaceuticals, a biopharmaceutical
company focused on research and development of therapeutic compounds for the treatment
of major endocrine, metabolic and cardiovascular diseases, today announced the appointment
of Rochelle Hanley, M.D., as chief medical officer. Dr. Hanley will oversee clinical
development of QuatRx’s product pipeline. Prior to joining QuatRx, Dr. Hanley was vice
president, clinical R&D site head of Pfizer’s Michigan Laboratories, where she oversaw the
clinical operations of Pfizer’s Michigan research and development facility. Dr. Hanley has
extensive experience managing clinical development, especially in metabolic disorders and
cardiovascular disease. In her career, Dr. Hanley has also held clinical development
management roles at both Glaxo Wellcome and Parke-Davis Pharmaceutical Research.
Other Management Changes
Along with Dr. Hanley’s appointment, Randy Whitcomb, M.D., a founder of QuatRx and its
chief medical officer since inception, has been appointed senior clinical research fellow. Dr.
Whitcomb will advise on research and development matters and will join the Company’s
Scientific Advisory Board.
Christopher Nicholas has been promoted to chief operating officer. Mr. Nicholas is a founder
of QuatRx and has served as its chief business officer since inception. Mr. Nicholas has more
than 25 years of global pharmaceutical marketing, business development and general
management experience at companies including Bayer, Hoechst/Roussel and Parke-Davis.
“Dr. Hanley and Dr. Whitcomb together provide unparalleled expertise which is closely
aligned with our therapeutic focus, and when combined with our new management structure,
position us well for the effective management of our growing and advancing portfolio of
clinical stage programs, including Ophena, fispemifene and Asord,” said Robert L.
Zerbe, M.D., president and chief executive officer of QuatRx Pharmaceuticals.
- more -

2/
About QuatRx
QuatRx Pharmaceuticals Company is focused on discovering, licensing, developing and
commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic
areas. QuatRx currently has four product candidates in clinical development. QuatRx’s two
lead compounds treat hormone deficiencies that result from aging in women and men.
Ophena is in Phase III development initially for the treatment of vaginal atrophy, a
common problem associated with estrogen deficiency in post-menopausal women.
Fispemifene, a treatment for testosterone deficiency, is in Phase II clinical testing. QuatRx
also has QRX-431, a product candidate for the treatment of elevated cholesterol levels, and
Asord, a topical product candidate for the treatment of mild to moderate psoriasis, which
has completed a Phase IIb clinical trial.
# # #